Solid Biosciences LLC Cash Flow-to-Debt Ratio
Solid Biosciences LLC cash flow-to-debt ratio. Solid Biosciences LLC (SLDB) has a Cash Flow-to-Debt Ratio of -1.13x as of June 2026, meaning its operating cash flow of $-52.59 Million could theoretically repay -1% of its total liabilities ($46.51 Million) in one year. See financial flexibility index of Solid Biosciences LLC to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Solid Biosciences LLC (2015–2025)
Cash flow-to-debt ratio of Solid Biosciences LLC from 2015 to 2025. Historical debt coverage capacity for Solid Biosciences LLC across 11 annual periods. Check SLDB total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Solid Biosciences LLC Cash Flow-to-Debt Ratio by Year (2015–2025)
Solid Biosciences LLC cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Solid Biosciences LLC. For the full cash flow conversion analysis, see Solid Biosciences LLC (SLDB) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.98x | $-156.29 Million | $52.53 Million | ▼ -53.0% |
| 2024 | -1.95x | $-100.01 Million | $51.42 Million | ▲ +20.6% |
| 2023 | -2.45x | $-94.18 Million | $38.46 Million | ▼ -21.4% |
| 2022 | -2.02x | $-97.98 Million | $48.59 Million | ▲ +37.3% |
| 2021 | -3.22x | $-77.76 Million | $24.17 Million | ▼ -122.2% |
| 2020 | -1.45x | $-56.60 Million | $39.08 Million | ▲ +63.4% |
| 2019 | -3.96x | $-92.71 Million | $23.42 Million | ▲ +18.7% |
| 2018 | -4.87x | $-70.20 Million | $14.41 Million | ▼ -1426.1% |
| 2017 | -0.32x | $-43.22 Million | $135.45 Million | ▼ -24.5% |
| 2016 | -0.26x | $-20.12 Million | $78.52 Million | ▼ -360.9% |
| 2015 | -0.06x | $-4.20 Million | $75.62 Million | — |